Getting a drug approved in multiple countries simultaneously requires filing the same information with dozens of different national regulatory authorities, each with their own systems, formats, and timelines.
For most pharmaceutical and biotech companies, that process involves manual reconciliation between internal systems, significant duplication of effort, and a submission timeline that stretches well beyond what the underlying science should require.
Accumulus Technologies, a San Francisco-based SaaS company spun out of regulatory-tech nonprofit Accumulus Synergy last August, has been building a cloud platform to address exactly that bottleneck. Today it launched the Accumulus Connector, a new capability designed to make that platform accessible directly from within the systems companies already use.
The đź’ś of EU tech
The latest rumblings from the EU tech scene, a story from our wise ol' founder Boris, and some questionable AI art. It's free, every week, in your inbox. Sign up now!
The core of Accumulus Technologies' offering is its regulatory network: a live platform connected to more than 70 national regulatory authorities, up from the 60-plus countries the system covered at the time of the August 2025 spinout.
Drug and biotech companies use the platform to manage simultaneous submissions across jurisdictions, enabling what the industry calls “reliance pathways”, a mechanism by which regulators in one country can leverage the review work of a regulator in another, shortening the time a therapy takes to reach patients in markets that might otherwise be deprioritised.
The Sanofi case announced in November 2024, while the platform still sat within Accumulus Synergy, illustrated the practical application: multi-regulator submissions managed simultaneously through a single interface rather than separately coordinated across each jurisdiction.
The Connector extends that network into a new integration layer. Previously, using the Accumulus platform required companies to work within the platform itself, with data moving between it and their own systems of record through manual reconciliation or custom integration work.
The Connector makes the network directly accessible from within those existing systems, ERP platforms, regulatory information management systems, document management tools, moving data bi-directionally between them and the regulatory network in real time.
Chanille Juneau, Chief Product and Technology Officer, described the design intent as meeting organisations “where they are,” without requiring them to migrate away from established infrastructure. The Connector is available to existing Accumulus platform subscribers.
The company is also positioning the integration layer as running in both directions: not just pharma companies connecting their systems to regulators, but regulators connecting their own systems into the Accumulus platform as well, creating what it describes as a “bi-directional network across industry and authorities.”Â
Accumulus Technologies is a young commercial entity, it formally separated from Accumulus Synergy only eight months ago, though the platform it commercialises launched in February 2024 and the underlying nonprofit had been building the ecosystem for several years before that, backed by founding sponsors from the major global pharmaceutical companies.
Francisco Nogueira, who built the platform from within Accumulus Synergy, serves as CEO. The Connector launch is the company's first major platform capability announcement since the spinout, and reflects the central tension in its commercial model: selling SaaS infrastructure to an industry that is structurally conservative, deeply regulated, and has historically treated data exchange between companies and regulators as a sensitive enough domain that it required a nonprofit intermediary to build the trust infrastructure first.